FDA approves Aurobindo's OTC cetirizine liquid
This article was originally published in The Tan Sheet
Executive Summary
The agency approves Aurobindo Pharma Limited's cetirizine hydrochloride solution, which the Hyderabad, India-based firm plans to launch "shortly." The product is the generic equivalent of McNeil Consumer Healthcare's Children's Zyrtec Allergy and Children's Zyrtec Hives Relief, both oral solutions containing cetirizine HCl and packaged in 1 mg/mL bottles. It will join the growing number of products in the category, which for the 52 weeks ended Jan. 24 had sales of $630.9 million, according to data from Information Resources, Inc. a Chicago-based market research firm. Private-label products in the category sold $149.3 million in the same period, while Johnson & Johnson/McNeil's liquid and powder Zyrtec products sold $26.4 million and Schering-Plough's Claritin liquid/powder products sold $12.7 million
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.